Is Intracellular Stock a Good Investment?

Intracellular Investment Advice

ITCI

To provide specific investment advice or recommendations on Intracellular Th stock, we recommend investors consider the following general factors when evaluating Intracellular Th. This will help you to make an informed decision on whether to include Intracellular in one of your diversified portfolios:

Examine Intracellular's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Intracellular's leadership team and their track record. Good management can help Intracellular navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Intracellular's business and its evolving consumer preferences.
Compare Intracellular's performance and market position to its competitors. Analyze how Intracellular is positioned in terms of product offerings, innovation, and market share.
Check if Intracellular pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Intracellular's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in Intracellular Th stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Intracellular Th is a good investment.

Sell

Buy

Hold

Macroaxis provides investment recommendation on Intracellular to complement and cross-verify current analyst consensus on Intracellular Th. Our trade recommendations engine determines the entity's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon. To make sure Intracellular Th is not overpriced, please check out all Intracellular fundamentals, including its current ratio, market capitalization, and the relationship between the cash and equivalents and earnings per share . Given that Intracellular Th has a number of shares shorted of 1.82 M, we strongly advise you to confirm Intracellular Th market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Market Performance	OK	Details
Volatility	Very steady	Details
Hype Condition	Under hyped	Details
Current Valuation	Undervalued	Details
Odds Of Distress	Below Average	Details
Economic Sensitivity	Follows the market closely	Details
Investor Sentiment	Alarmed	Details
Analyst Consensus	Strong Buy	Details
Financial Strenth (F Score)	Healthy	Details
Financial Leverage	Not Rated	Details
Reporting Quality (M-Score)	Possible Manipulator	Details

Examine Intracellular Stock

Researching Intracellular's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 96.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.87. Intracellular Th had not issued any dividends in recent years.

To determine if Intracellular is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Intracellular's research are outlined below:

	The company reported the previous year's revenue of 464.37 M. Net Loss for the year was (139.67 M) with profit before overhead, payroll, taxes, and interest of 95.16 M.
	Intracellular Th currently holds about 628.74 M in cash with (124.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.64.
	Over 96.0% of the company shares are owned by institutional investors
	Latest headline from zacks.com: Why Is Intra-Cellular Up 2.2 percent Since Last Earnings Report

Intracellular Quarterly Liabilities And Stockholders Equity

1.32 Billion

Intracellular uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Intracellular Th. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intracellular's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	6th of March 2024 Upcoming Quarterly Report	View
	2nd of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	6th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

Earnings surprises can significantly impact Intracellular's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Intracellular's investors have experienced.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
2024-08-07	2024-06-30	-0.19	-0.16	0.03	15
2024-10-30	2024-09-30	-0.2	-0.25	-0.05	25
2014-11-03	2014-09-30	-0.28	-0.22	0.06	21
2014-05-05	2014-03-31	-0.23	-0.17	0.06	26
2021-02-25	2020-12-31	-0.85	-0.76	0.09	10
2017-11-08	2017-09-30	-0.62	-0.53	0.09	14
2014-08-12	2014-06-30	-0.24	-0.15	0.09	37
2017-05-10	2017-03-31	-0.72	-0.62	0.1	13

Know Intracellular's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Intracellular is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intracellular Th backward and forwards among themselves. Intracellular's institutional investor refers to the entity that pools money to purchase Intracellular's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Franklin Resources Inc	2024-09-30	1.8 M
Clearbridge Advisors, Llc	2024-09-30	1.7 M
Geode Capital Management, Llc	2024-09-30	1.7 M
Perceptive Advisors Llc	2024-09-30	1.6 M
Deep Track Capital, Lp	2024-09-30	1.6 M
Suvretta Capital Management, Llc	2024-06-30	1.6 M
T. Rowe Price Associates, Inc.	2024-06-30	1.4 M
Gw&k Investment Management, Llc	2024-09-30	1.4 M
Holocene Advisors, Lp	2024-09-30	1.4 M
Fmr Inc	2024-09-30	11.1 M
Vanguard Group Inc	2024-09-30	9.6 M

Note, although Intracellular's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Intracellular's market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.08 B.

Market Cap

7.21 Billion

Intracellular's profitablity analysis

	Last Reported	Projected for Next Year
Return On Tangible Assets	(0.19)	(0.20)
Return On Capital Employed	(0.26)	(0.28)
Return On Assets	(0.19)	(0.20)
Return On Equity	(0.24)	(0.25)

The company has Profit Margin (PM) of (0.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.22) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.22.

Determining Intracellular's profitability involves analyzing its financial statements and using various financial metrics to determine if Intracellular is a good buy. For example, gross profit margin measures Intracellular's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Intracellular's profitability and make more informed investment decisions.

Evaluate Intracellular's management efficiency

Intracellular Th has return on total asset (ROA) of (0.0745) % which means that it has lost $0.0745 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.099) %, meaning that it created substantial loss on money invested by shareholders. Intracellular's management efficiency ratios could be used to measure how well Intracellular manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.2. The current Return On Capital Employed is estimated to decrease to -0.28. As of now, Intracellular's Non Currrent Assets Other are increasing as compared to previous years. The Intracellular's current Deferred Long Term Asset Charges is estimated to increase to about 635.1 K, while Total Assets are projected to decrease to under 410.9 M.

	Last Reported	Projected for Next Year
Book Value Per Share	6.17	5.03
Tangible Book Value Per Share	6.17	5.03
Enterprise Value Over EBITDA	(42.41)	(40.29)
Price Book Value Ratio	11.61	7.67
Enterprise Value Multiple	(42.41)	(40.29)
Price Fair Value	11.61	7.67
Enterprise Value	6.7 B	7.1 B

Intracellular showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.

Beta

0.973

Basic technical analysis of Intracellular Stock

As of the 30th of November, Intracellular retains the Market Risk Adjusted Performance of 0.359, risk adjusted performance of 0.1046, and Downside Deviation of 1.56. Intracellular technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Intracellular's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intracellular insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intracellular's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intracellular insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Van Nostrand Robert L over a week ago Acquisition by Van Nostrand Robert L of 1567 shares of Intracellular subject to Rule 16b-3
		Halstead Michael over two weeks ago Disposition of 22869 shares by Halstead Michael of Intracellular at 23.94 subject to Rule 16b-3
		Riggs Rory B over two months ago Acquisition by Riggs Rory B of 246 shares of Intracellular at 73.17 subject to Rule 16b-3
		Sharon Mates over three months ago Disposition of 34396 shares by Sharon Mates of Intracellular at 12.73 subject to Rule 16b-3
		Sharon Mates over three months ago Disposition of 35604 shares by Sharon Mates of Intracellular at 12.73 subject to Rule 16b-3
		Sharon Mates over three months ago Disposition of 40513 shares by Sharon Mates of Intracellular at 17.57 subject to Rule 16b-3
		Sharon Mates over three months ago Disposition of 22713 shares by Sharon Mates of Intracellular at 17.57 subject to Rule 16b-3
		Sharon Mates over three months ago Disposition of 28680 shares by Sharon Mates of Intracellular at 17.57 subject to Rule 16b-3
		Sharon Mates over three months ago Disposition of 380 shares by Sharon Mates of Intracellular at 17.57 subject to Rule 16b-3
		Sharon Mates over three months ago Disposition of 53013 shares by Sharon Mates of Intracellular at 17.57 subject to Rule 16b-3
		Mark Neumann over three months ago Disposition of 18714 shares by Mark Neumann of Intracellular at 36.89 subject to Rule 16b-3
		Halstead Michael over three months ago Acquisition by Halstead Michael of 7907 shares of Intracellular subject to Rule 16b-3

Intracellular's Outstanding Corporate Bonds

Intracellular issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Intracellular Th uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Intracellular bonds can be classified according to their maturity, which is the date when Intracellular Th has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Boeing Co 2196 Corp Bond US097023DG73	View
	HSBC Holdings PLC Corp Bond US404280DR76	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	Intesa Sanpaolo 571 Corp Bond US46115HAW79	View
	ISPIM 77 Corp Bond US46115HAU14	View
	ISPIM 3875 12 JAN 28 Corp Bond US46115HBD89	View
	ISPIM 4375 12 JAN 48 Corp Bond US46115HBE62	View
	ISPIM 3875 14 JUL 27 Corp Bond US46115HBB24	View

View All Intracellular Corporate Bonds

Understand Intracellular's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Intracellular's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	0.1046
	Market Risk Adjusted Performance	0.359
	Mean Deviation	1.33
	Semi Deviation	1.31
	Downside Deviation	1.56
	Coefficient Of Variation	777.57
	Standard Deviation	2.08
	Variance	4.34
	Information Ratio	0.0626
	Jensen Alpha	0.1637
	Total Risk Alpha	(0.09)
	Sortino Ratio	0.0836
	Treynor Ratio	0.349
	Maximum Drawdown	16.17
	Value At Risk	(2.53)
	Potential Upside	3.04
	Downside Variance	2.43
	Semi Variance	1.71
	Expected Short fall	(1.59)
	Skewness	2.13
	Kurtosis	11.77

	Risk Adjusted Performance	0.1046
	Market Risk Adjusted Performance	0.359
	Mean Deviation	1.33
	Semi Deviation	1.31
	Downside Deviation	1.56
	Coefficient Of Variation	777.57
	Standard Deviation	2.08
	Variance	4.34
	Information Ratio	0.0626
	Jensen Alpha	0.1637
	Total Risk Alpha	(0.09)
	Sortino Ratio	0.0836
	Treynor Ratio	0.349
	Maximum Drawdown	16.17
	Value At Risk	(2.53)
	Potential Upside	3.04
	Downside Variance	2.43
	Semi Variance	1.71
	Expected Short fall	(1.59)
	Skewness	2.13
	Kurtosis	11.77

Consider Intracellular's intraday indicators

Intracellular intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Intracellular stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	6243.62
	Daily Balance Of Power	(0.48)
	Rate Of Daily Change	0.99
	Day Median Price	85.61
	Day Typical Price	85.62
	Price Action Indicator	(0.43)
	Period Momentum Indicator	(0.94)
	Relative Strength Index	83.64

Intracellular Corporate Filings

F4	14th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
13A	12th of November 2024 An amended filing to the original Schedule 13G	View Verify
8K	5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about	View Verify
13A	10th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934	View Verify

Intracellular time-series forecasting models is one of many Intracellular's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Intracellular's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Intracellular Stock media impact

Far too much social signal, news, headlines, and media speculation about Intracellular that are available to investors today. That information is available publicly through Intracellular media outlets and privately through word of mouth or via Intracellular internal channels. However, regardless of the origin, that massive amount of Intracellular data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.

A primary focus of Intracellular news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Intracellular relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Intracellular's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Intracellular alpha.

Intracellular Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Intracellular can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.

Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Intracellular Corporate Management

CPA CPA	CFO, Fin	Profile
Suresh MD	Executive Officer	Profile
Karen Esq	Senior Officer	Profile
Willie MD	Senior Development	Profile

When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock: